Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Pujan V. Padsala, Harmish A Asodariya, Yash S Shah, Dip Ranpariya, Dr. Hiral Panchal
When treating patients from various origins with distinct cultures, metabolisms, and needs, interindividual variability is becoming a more widespread concern. Because dose modification typically relies on empirical techniques, there is a strong probability that undesirable side effects may manifest.The pharmaceutical industry is being revolutionized by three-dimensional (3D) printed pharmaceuticals as prospective instruments to create individualized therapies tailored to each patient's unique needs,taking into consideration their age, weight,pharmacogenetic,comorbidities, pharmacogenetic,and pharmacokinetic features. Only three of the various processes used in additive manufacturing, or 3D printing, are primarily employed in the 3D printing of pharmaceuticals: printing-based inkjet systems, nozzle-based deposition systems, and laser-based writing systems. Each method has a number of downsides, and the kinds of polymers thatare easily accessible don't necessarily have the best qualities for each medicine. The purpose of this study is to provide an overview of the current methods used in 3D printing medications, highlighting their advantages and shortcomings as well as the necessary polymers and medications for a successful print. Also covered will be the main applications
of these approaches.